Skip to main content
SpringerLink
Log in

Off-label-Indikationen für topisches Tacrolimus

Off-label indications for topical tacrolimus

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Der topische Calcineurinantagonist Tacrolimus hat wegen seines Sicherheitsprofils in der Dermatologie mittlerweile einen festen Platz in der Behandlung verschiedener Formen des Ekzems inne. Daneben sind verschiedene Off-label-Indikationen klinisch erprobt worden, bei denen Tacrolimus-Salbe klinische Erfolge erzielt hat. Im Folgenden wird die Off-label-Behandlung von Vitiligo, seborrhoischer Dermatitis, Steroidentzugsdermatitis, perioraler Dermatitis, Rosazea und Lichen sclerosus vorgestellt.

Abstract

The topical calcineurin antagonist tacrolimus plays an important role in the treatment of different forms of eczema because of its favorable risk profile. In addition, different off-label indications have been clinically tested where tacrolimus ointment has achieved clinical improvement. This article discusses off-label treatment of vitiligo, seborrheic dermatitis, steroid rosacea, perioral dermatitis, rosacea and lichen sclerosus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Bamford JT, Elliott BA, Haller IV (2004) Tacrolimus effect on rosacea. J Am Acad Dermatol 50:107–108

    Article  PubMed  Google Scholar 

  2. Braza TJ, DiCarlo JB, Soon SL, McCall CO (2003) Tacrolimus 0.1 % ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 148:1242–1244

    Article  PubMed  CAS  Google Scholar 

  3. Connolly M, Kennedy C (2004) Exfoliative cheilitis successfully treated with topical tacrolimus. Br J Dermatol 151:241–242

    Article  PubMed  CAS  Google Scholar 

  4. Dahlman-Ghozlan K, Hedblad MA, Krogh G von (1999) Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05 % cream: a retrospective clinical and histopathological study. J Am Acad Dermatol 40:451–457

    Article  PubMed  CAS  Google Scholar 

  5. Dirschka T, Tronnier H, Fölster-Holst R (2004) Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 150:1136–1141

    Article  PubMed  CAS  Google Scholar 

  6. Ebert AK, Rösch WH, Vogt T (2008) Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol 54:932–937

    Article  PubMed  CAS  Google Scholar 

  7. Freeman AK, Serle J, Van Veldhuisen P et al (2004) Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 73:267–271

    PubMed  Google Scholar 

  8. Goldman D (2001) Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 44:995–998

    Article  PubMed  CAS  Google Scholar 

  9. Grimes PE et al (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52–61

    Article  PubMed  Google Scholar 

  10. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54:1–15

    Article  PubMed  Google Scholar 

  11. Hengge UR, Krause W, Hofmann H et al (2006) Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 155:1021–1028

    Article  PubMed  CAS  Google Scholar 

  12. Kanwar AJ et al (2004) Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 29:589–592

    Article  PubMed  CAS  Google Scholar 

  13. Kawakami T, Soma Y, Morita E et al (2001) Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 203:32–37

    Article  PubMed  CAS  Google Scholar 

  14. Lepe V et al (2003) A double-blind randomized trial of 0.1 % tacrolimus vs 0.05 % clobetasol for the treatment of childhood vitiligo. Arch Dermatol 139:581–585

    Article  PubMed  CAS  Google Scholar 

  15. Mehrabi D, Pandya AG (2006) A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1 % tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 142:927–929

    Article  PubMed  Google Scholar 

  16. Oyama N, Chan I, Neill SM et al (2003) Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 362:118–123

    Article  PubMed  CAS  Google Scholar 

  17. Passeron T et al (2004) Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 140:1065–1069

    Article  PubMed  CAS  Google Scholar 

  18. Powell JJ, Wojnarowska F (1999) Lichen sclerosus. Lancet 353:1777–1783

    Article  PubMed  CAS  Google Scholar 

  19. Silverberg NB et al (2004) Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 51:760–766

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. U.R. Hengge bekam in der Vergangenheit Honorare der Firmen Astellas und Meda. Alle im vorliegenden Manuskript beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zuständigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gemäß der Deklaration von Helsinki von 1975 (in der aktuellen, überarbeiteten Fassung) durchgeführt. Von allen beteiligten Patienten liegt eine Einverständniserklärung vor.

Author information

Authors and Affiliations

  1. Hautzentrum Prof. Hengge, Immermannstr. 10, 40210, Düsseldorf, Deutschland

    U.R. Hengge

Authors
  1. U.R. Hengge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U.R. Hengge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hengge, U. Off-label-Indikationen für topisches Tacrolimus. Hautarzt 64, 752–756 (2013). https://doi.org/10.1007/s00105-013-2594-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-013-2594-1

Schlüsselwörter

Keywords

Search

Navigation